Nonatherosclerotic coronary artery disease

Article written and reviewed by Dr Luca Moretti

Nonatherosclerotic coronary artery disease comprises conditions in which myocardial flow is impaired by a wall abnormality, embolic material, thrombosis not originating from an atherosclerotic plaque, vascular inflammation, pathological dilation, or dynamic compression. They are not one disease and do not share universal treatment. Their common denominator is the absence of a dominant atherosclerotic substrate. Diagnosis must identify the mechanism actually responsible for ischemia.
These disorders are particularly relevant when infarction affects a young person, a pregnant or postpartum woman, a patient with systemic disease, or someone without an atherosclerotic burden proportionate to the event. Age and risk factors guide probability but do not replace anatomy and pathophysiology. Clinical-angiographic discordance is a useful signal. An older or dyslipidemic person may also experience a nonatherosclerotic event.

MINOCA is sometimes improperly used as a synonym for nonatherosclerotic coronary disease. It actually provisionally describes myocardial injury with clinical features of possible infarction when angiography shows no epicardial coronary stenosis of 50 percent or greater. The cause may be atherosclerotic, nonatherosclerotic, or extracoronary. MINOCA is a working diagnosis. OCT, IVUS, and cardiac magnetic resonance imaging may convert that label into an etiologic diagnosis.
Some forms almost always cause an acute event, such as dissection with severe true-lumen compression or an occluding embolus; others may be incidental, such as many myocardial bridges and some ectasias. Anatomical presence does not automatically prove causality, and symptom severity does not measure the danger of a finding. Causal correlation requires territorial and temporal consistency. Every finding must be compared with ischemia, myocardial injury, and alternative diagnoses.

Contemporary management is therefore phenotype-based. Stable SCAD tends to heal and is preferably observed; embolism requires identification and treatment of its source; vasculitis requires control of inflammation; aneurysm or ectasia requires assessment of size, flow, and thrombosis; a symptomatic bridge requires functional evidence. Causal therapy takes precedence over syndromic reflexes. Drugs appropriate for atherothrombotic infarction may be useless or risky in other mechanisms.

Etiology, risk factors, pathogenesis, and pathophysiology

In spontaneous coronary artery dissection, wall separation and an intramural hematoma compress the true lumen without trauma, a procedure, or atherosclerosis as the primary cause. An intimal tear allowing blood entry is the inside-out model; hemorrhage arising within the media is the outside-in model. The intramural hematoma is the decisive obstructive mechanism. Fibromuscular dysplasia, tortuosity, and pregnancy indicate arterial vulnerability, not a sufficient cause in every patient.
In coronary embolism, occluding material reaches the coronary artery from a distant site. Left atrial thrombi in atrial fibrillation, prosthetic or diseased valves, infectious vegetations, ventricular thrombi, and venous emboli through a right-to-left shunt are recognized sources; the embolic source determines prevention and treatment duration. Tumor material, air, fat, or calcium is possible but much less common than thromboembolism.

Nonatherosclerotic coronary thrombosis instead arises in situ without an eroded or ruptured plaque explaining the thrombus. Antiphospholipid antibody syndrome, cancer, essential thrombocythemia, polycythemia vera, heparin-induced immune thrombocytopenia, and certain thrombophilias may create a prothrombotic environment; primary thrombosis is a diagnosis of anatomical exclusion. A visible thrombus alone does not distinguish atherothrombosis, embolism, and local coagulation.
Coronary vasculitis results from inflammation of the wall or perivascular tissue. Kawasaki disease, polyarteritis nodosa, Takayasu arteritis, giant cell arteritis, Behçet disease, and IgG4-related disease may affect coronary arteries in different distributions; inflammatory injury may produce stenosis, thrombosis, aneurysm, or dissection. Histological categories and vessel size help, but coronary phenotype differs among vasculitides.

A coronary artery aneurysm is focal dilation, conventionally greater than 1.5 times the diameter of the adjacent normal segment. It may result from Kawasaki disease, vasculitides, connective tissue disorders, infection, trauma, or procedures, although atherosclerosis often coexists in adults and must be distinguished from genuinely nonatherosclerotic forms. Focal dilation alters wall tension and flow. Risk depends on cause, size, morphology, growth, and thrombus.
Coronary artery ectasia describes diffuse dilation, often defined as exceeding 1.5 times expected caliber for more than one third of vessel length. Its distinction from aneurysm is morphological and not absolute because both may coexist and share stasis, vortical flow, and thrombosis; blood stagnation promotes aggregation and microembolization. Not all ectasia is nonatherosclerotic, and the cause must be stated rather than presumed.

In myocardial bridging, a coronary segment, most often the left anterior descending artery, runs within the myocardium and is compressed during systole. Many bridges are benign because left coronary perfusion occurs mainly during diastole; depth, length, tachycardia, and delayed relaxation may nevertheless extend compression into diastole. Dynamic compression varies with heart rate and contractility. Functional significance must be demonstrated before the anatomical finding is considered causal.
Different mechanisms may converge in one patient. An inflammatory aneurysm may thrombose and embolize distally; vasculitis may cause dissection; SCAD may contain thrombus in the true lumen; a bridge may coexist with vasospasm and proximal plaque; pathophysiological overlaps do not erase causal hierarchy. Clinicians must establish which process initiated the event, which amplified it, and which are concomitant findings.

Pathological anatomy, classification, and progression

The coronary wall contains intima, media, and adventitia, and each disease group affects a different compartment. SCAD separates layers mainly within the outer media, vasculitis infiltrates and damages wall or adventitia, aneurysm and ectasia remodel overall caliber, while embolism and thrombosis primarily occupy the lumen. Damage topography guides appropriate imaging. Luminography may show the final effect without representing the wall process that produced it.
SCAD predominantly affects mid and distal segments, most often the left anterior descending tree. Angiographic classification distinguishes a double lumen and contrast staining in type 1, long smooth narrowing in type 2, focal atherosclerosis-like stenosis in type 3, and distal total occlusion in type 4; angiographic type 2 is most frequent. Many conservatively treated lesions spontaneously recover their caliber as the hematoma is resorbed.

An embolus tends to lodge at a bifurcation or in a distal segment but may affect any branch and several territories. A sharp cutoff, absence of diffuse atheroma, and simultaneous thrombi increase suspicion without being absolute proof; embolic distribution may change after fragmentation or aspiration. A lysed embolus may leave normal angiography despite MRI documenting a territorial infarction.
In situ thrombosis may be focal, extensive, or recurrent and may organize, recanalize, or dissolve. OCT may identify erosion or rupture obscured by thrombosis, preventing incorrect nonatherosclerotic classification; it must be used only when diagnostic benefit outweighs risk. Thrombus morphology does not determine origin with certainty. Histology, wall imaging, and hematological context may complement one another.

Vasculitides produce combinations of thickening, edema, stenosis, occlusion, dilation, aneurysm, and fibrosis. Kawasaki disease favors coronary aneurysms, Takayasu arteritis may affect ostia and proximal segments, Behçet disease may produce aneurysms and thrombosis, and IgG4-related disease may create a pericoronary cuff; the anatomical pattern narrows the differential diagnosis. No isolated morphology replaces the clinical, laboratory, and systemic imaging criteria of the causal disease.
Saccular and fusiform aneurysms have different geometry and flow; giant forms use different thresholds in pediatric and adult populations and must not be defined by one universal value. Ectasia is often classified by the number and extent of affected vessels, as in the Markis classification. The dilational burden exceeds maximum diameter alone. Mural thrombus, inflow, outflow, collaterals, and progression complete assessment.

Myocardial bridging is described by the artery involved, length, depth, percentage compression, and relation to side branches. CCTA defines anatomy; angiography and IVUS show compression and morphology, while diastolic indices with inotropic provocation assess the functional consequence; a deep phenotype may exert greater compression. However, no anatomical threshold alone predicts ischemia in every person.
Temporal evolution is another diagnostic criterion. Healing of long stenosis supports SCAD; migration or disappearance of a defect suggests embolism or thrombus; variation with disease activity suggests vasculitis; structural persistence characterizes aneurysm, ectasia, and bridging; selective follow-up may clarify the mechanism. Repeating invasive examinations without a concrete clinical question instead adds risk without proven benefit.

Clinical manifestations

The most important presentation is an acute coronary syndrome with chest pain, ECG changes, and increased troponin. SCAD, embolism, thrombosis, and vasculitis may cause STEMI or NSTEMI, while aneurysm and ectasia become acute mainly when complicated by thrombosis or embolization; the infarction phenotype does not automatically reveal etiology. Initial management of instability proceeds together with investigation of the mechanism.
SCAD predominantly affects women and often presents with sudden pain; nausea, dyspnea, sweating, arrhythmias, shock, or cardiac arrest reflect the extent and ischemic territory. Pregnancy-associated SCAD tends to have more proximal or multivessel involvement and greater severity than many nongestational SCADs. The demographic profile raises suspicion but must not exclude men, older adults, or patients with atherosclerotic factors.

Coronary embolism may arise during atrial fibrillation, endocarditis, prosthetic thrombosis, or intracardiac procedures, but its source may initially be silent. Fever, a new murmur, systemic emboli, concomitant stroke, or absence of atheroma suggests specific mechanisms; extracardiac signs are part of coronary assessment. Failure to find a source at the first evaluation does not prove primary thrombosis.
Primary thrombosis may be the first sign of antiphospholipid antibody syndrome, cancer, or a myeloproliferative neoplasm. Previous venous or arterial thromboses, recurrent miscarriage, thrombocytosis, erythrocytosis, heparin exposure, or family history guide testing; the thrombotic history selects tests. Indiscriminate screening for every thrombophilia after any infarction produces uncertain results and is unjustified.

In vasculitis, ischemia and infarction may accompany fever, weight loss, headache, claudication, neuropathy, skin lesions, arthralgia, or renal and ocular abnormalities. Kawasaki disease leaves coronary sequelae that may present in adulthood many years after the childhood episode. The systemic history may be decisive. Normal inflammatory markers do not exclude treated vasculitis or an inactive fibrotic sequela.
Aneurysm and ectasia often remain asymptomatic until stasis, thrombus, or an associated stenosis produces angina or infarction. Pain does not necessarily mean expansion, and coronary rupture is much less common than thrombosis, although it can be catastrophic in specific giant or infected forms; a thrombotic complication dominates many presentations. Risk must not be automatically transferred from aortic aneurysms.

Symptomatic myocardial bridging mainly causes exertional angina, dyspnea, palpitations, or rarely syncope, worsening with tachycardia and increased contractility. Most bridges found on CCTA do not cause ischemia and cannot explain atypical pain by anatomical presence alone; exertional dependence supports functional plausibility. Vasospasm, microvascular dysfunction, and proximal plaque may still contribute.
Persistent or recurrent pain after SCAD is common and may result from extension, vasomotor abnormalities, post-infarction perception, or noncardiac causes. Every new episode is assessed by duration, ECG, troponin, and stability, avoiding both automatic repeat angiography and reassurance without evaluation; post-SCAD pain does not always mean recurrence. Syncope, instability, or objective abnormalities lower the diagnostic threshold.

Investigations and diagnosis

In acute presentations, serial ECGs, high-sensitivity troponin, vital signs, and echocardiography are rapidly obtained according to stability and presentation; they document ischemia, myocardial injury, function, and complications but do not reliably distinguish plaque from a nonatherosclerotic mechanism; syndromic diagnosis precedes causal diagnosis. Shock, malignant arrhythmia, or persistent ischemia requires urgent treatment while etiology is defined.
Invasive coronary angiography remains central in infarction and may identify a double lumen, long stenosis, occlusion, embolic defect, thrombus, aneurysm, ectasia, and systolic compression. It is two-dimensional luminography influenced by projection and contrast and may not directly show the wall; a mechanistic reading goes beyond stenosis percentage. Cautious injections and gentle manipulation are essential when vascular fragility is suspected.

OCT provides high resolution for intima, thrombus, discontinuities, false lumen, and superficial hematoma; IVUS penetrates more deeply and may outline hematoma extent without the same need for high-pressure blood clearance. Both may extend dissection or cause iatrogenic injury. Intracoronary imaging is reserved for consequential uncertainty. It is not performed merely to further document angiographically certain SCAD intended for conservative treatment.
CCTA describes the wall, course, bridge, aneurysm, and large dissected segments, but resolution and motion limit distal branches. Negative CCTA does not exclude acute small-vessel SCAD and does not replace angiography in high-risk infarction; coronary tomography is particularly useful for structural abnormalities. It may be selected for follow-up when the affected segment is sufficiently large and proximal.

Cardiac magnetic resonance imaging identifies ischemic injury distribution, edema, scar, and alternative diagnoses such as myocarditis or Takotsubo syndrome. In MINOCA it should be performed early when available because diagnostic yield falls as acute findings resolve; tissue characterization distinguishes infarction from mimics. It does not directly identify the embolic source or coronary lesion type in every case.
Investigation of embolism integrates rhythm monitoring, transthoracic or transesophageal echocardiography, assessment of valves, appendage, ventricle, and shunts, blood cultures when endocarditis is suspected, and procedural history. Thrombophilia testing is instead targeted to age, recurrence, multiple sites, and systemic signs; the etiologic pathway avoids random panels. Laboratory results must be confirmed and interpreted outside acute-phase interference when required.

Suspected vasculitis is assessed by integrating inflammatory markers, blood count, renal function, selected autoantibodies, vascular imaging, and rheumatological evaluation. PET, CCTA, angiography, magnetic resonance imaging, and biopsy answer different questions; coronary biopsy is not an ordinary diagnostic procedure. Systemic activity guides immunological treatment. An isolated aneurysm does not diagnose vasculitis, and positive serology does not prove coronary involvement.
In myocardial bridging, significance is investigated with provocative testing and diastole-oriented physiology. Dobutamine reproduces tachycardia and inotropy better than adenosine for this mechanism, while dFFR, Doppler, and IVUS may document hemodynamic abnormality and compression; functional evidence selects truly symptomatic patients. Final diagnosis requires concordance among bridge location, ischemia, symptoms, and absence of a more convincing explanation.

Treatment and prognosis

Initial treatment stabilizes ischemia, arrhythmias, congestion, and shock according to presentation but is corrected as soon as the mechanism is recognized. No drug package applies to all nonatherosclerotic coronary diseases, and presentation as infarction alone does not justify identical chronic therapy; therapeutic precision reduces harm and recurrence. Indications for antiplatelet drugs, anticoagulants, statins, and revascularization must be justified separately.
For stable SCAD with preserved flow, inpatient observation and conservative management are preferred because the wall frequently heals and PCI risks false-lumen entry and hematoma extension. Revascularization is considered for persistent ischemia, instability, left main disease, or high-risk proximal anatomy. Spontaneous healing supports caution. Thrombolysis is avoided, and anticoagulation is reassessed once diagnosis is certain unless another indication exists.

For embolism, aspiration or PCI may restore flow in selected cases, while prevention depends on the source. Atrial fibrillation requires risk-based anticoagulation, endocarditis needs antibiotics and surgical assessment, prosthetic or ventricular thrombus follows its own protocols, and a paradoxical shunt is discussed in the proper context. Source control prevents new events. A stent is unnecessary when the underlying vessel is intact and flow recovers.
In primary thrombosis, flow restoration is balanced with control of the prothrombotic state. Anticoagulation, antiplatelet treatment, cytoreduction, or immunomodulation depends on diagnosis, bleeding risk, and stent presence; angiography alone provides no single duration; the hematological disease becomes the prognostic target. Low-risk inherited thrombophilia does not automatically justify lifelong anticoagulation.

Coronary vasculitis requires treatment of the specific disease with glucocorticoids, immunosuppressants, or biologics according to rheumatological guidelines, together with ischemia management. Revascularization is planned after inflammation is controlled when possible because persistent activity increases restenosis, thrombosis, and complications. Vascular remission protects the intervention. In emergencies, however, myocardial salvage cannot await full immunological control.
Aneurysm and ectasia require individualized therapy based on etiology, thrombus, stenosis, size, and progression. Antiplatelet therapy or anticoagulation is selected according to thrombotic and bleeding risk, while covered stents, embolization, ligation, bypass, or reconstruction are options for complex anatomy, not universal standards. A Heart Team discusses the anatomical strategy. Comparative evidence remains limited and many recommendations derive from registries and series.

In symptomatic bridging, beta-blockers reduce heart rate and contractility and are often first-line; calcium channel blockers are useful when vasospasm coexists or beta-blockade is inappropriate. Nitrates may accentuate compression and are generally avoided as bridge-specific therapy; antianginal therapy precedes intervention. Surgical myotomy or bypass is reserved for documented ischemia and refractory symptoms in selected anatomy.
Prognosis cannot be summarized by the term nonatherosclerotic. Healed SCAD retains recurrence risk, embolism recurs if its source persists, active vasculitis may progress rapidly, a thrombosed aneurysm may cause new events, and an incidental bridge may not alter survival; individual risk depends on mechanism. Ventricular function, infarct extent, comorbidities, and adherence complete the estimate.

Complications

The most important shared consequence is myocardial infarction, whose extent depends on vessel, location, occlusion duration, and collaterals. Microvascular obstruction, edema, and necrosis may persist after flow restoration, causing systolic dysfunction and remodeling; myocardial injury follows shared final pathways. The coronary cause remains essential for preventing a second occlusion.
Extensive ischemia may cause ventricular tachycardia, ventricular fibrillation, block, ischemic mitral regurgitation, pulmonary edema, and cardiogenic shock; these complications require intensive care regardless of atherosclerotic or nonatherosclerotic origin. Electrical instability may be the first manifestation. Initially depressed ventricular function may recover or progress to heart failure according to the amount of necrotic myocardium.

SCAD may extend during the first days, involve side branches, or later recur in another segment. Catheters, wires, injections, and stents may propagate hematoma or create a new iatrogenic dissection, so every procedure needs concrete benefit; a procedural complication is part of the decision. Conservative management does not mean absence of surveillance during the vulnerable phase.
Emboli and thrombi may fragment and occlude the microcirculation, causing no-reflow and multiple small infarctions. With an endocarditic source, infection and tissue fragility increase the risk of mycotic aneurysm, abscess, and new systemic emboli; distal microembolization limits tissue recovery. Angiographic patency of the epicardial vessel alone does not ensure normal myocardial perfusion.

Vasculitis, aneurysm, and ectasia may be complicated by mural thrombus, embolization, progressive stenosis, occlusion, and, less often, rupture or fistula. Anatomical transformation may continue as symptoms lessen, particularly when inflammation is uncontrolled or the lesion is large; morphological surveillance is personalized. Frequency and method depend on etiology, caliber, growth, and consequences of possible intervention.
Serious complications of myocardial bridging are rare compared with the high frequency of the anatomical finding, but ischemia, arrhythmias, and infarction are described in functionally significant phenotypes. Attributing every sudden death to an incidental bridge overstates causality, especially without adequate physiological or pathological evidence. Arrhythmic causality requires rigor. Cardiomyopathies, channelopathies, vasospasm, and other causes of electrical instability must be excluded.

A frequent complication is therapeutic error caused by incomplete classification. Thrombolysis in SCAD, unwarranted anticoagulation of an intramural hematoma, immunosuppression of a noninflammatory aneurysm, or stenting an embolus in a healthy vessel may increase harm; mechanistic iatrogenesis is preventable. When etiology remains uncertain, probabilities, risks, and a reassessment plan must be explicit.
Finally, recurrent pain, fear of recurrence, activity restriction, and diagnostic uncertainty may impair quality of life even with preserved ventricular function. Precise information, rehabilitation, and psychological support are especially important after SCAD and infarction at a young age; global recovery is not merely angiographic healing. Coordinated follow-up reduces both unnecessary medicalization and underestimation of new objective warning signs.